2021
Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study
Efe C, Dhanasekaran R, Lammert C, Ebik B, la Tijera F, Aloman C, Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Aldana A, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology 2021, 73: 2099-2109. PMID: 33713486, PMCID: PMC8250536, DOI: 10.1002/hep.31797.Peer-Reviewed Original ResearchConceptsSevere COVID-19Chronic liver diseaseAutoimmune hepatitisLiver injuryMulticenter studyCOVID-19Causes of CLDPropensity score-matched cohortSevere COVID-19 outcomesContinuation of immunosuppressionMaintenance of immunosuppressionOutcomes of patientsIntensive care admissionUse of antiviralsInternational multicenter studyCOVID-19 outcomesCOVID-19 diagnosisContinued immunosuppressionCare admissionCause mortalityIndependent predictorsMedian ageLiver diseaseMechanical ventilationRetrospective study
2020
Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol
Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology & Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBile Acids and SaltsBiomarkersCholangitis, SclerosingCytokinesDrug Therapy, CombinationFemaleFenofibrateHumansInflammation MediatorsLiverLiver Cirrhosis, BiliaryLiver Function TestsMaleMiddle AgedPPAR alphaPrincipal Component AnalysisRetrospective StudiesTreatment OutcomeUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisPrimary biliary cholangitisBile acid metabolismSclerosing cholangitisBiliary cholangitisBile acidsAcid metabolismPeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaRetrospective observational studyBeneficial clinical effectsCholestatic liver diseasePro-inflammatory cytokinesBile acid metabolitesHealthy control subjectsBile acid poolSerum alkaline phosphataseAminotransferase abnormalitiesUrsodiol therapyFenofibrate therapyPartial respondersBile acid precursorsClinical effectsFenofibrate treatmentLiver disease
2017
Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis
Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis. Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/mcg.0000000000000591.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAlanine TransaminaseAlkaline PhosphataseBile Acids and SaltsCholagogues and CholereticsCholangitis, SclerosingCholestenonesDrug Therapy, CombinationFemaleHumansLiverLiver Function TestsMaleMiddle AgedPilot ProjectsTreatment OutcomeTretinoinUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisUrsodeoxycholic acidAlanine aminotransferaseUDCA monotherapyPrimary endpointSclerosing cholangitisMedian serum alanine aminotransferasePilot studyWeeks of therapyMarkers of inflammationSerum alanine aminotransferaseRetinoic acidAlkaline phosphataseAll-Trans Retinoic AcidSerum ALP levelsHuman pilot studyCombination of ATRAAddition of ATRABile acid synthesisTrans retinoic acidExploratory pilot studyALT levelsAccepted therapyWeek 12C4 levels
2013
The role of macrophage migration inhibitory factor in autoimmune liver disease
Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic‐Paterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2013, 59: 580-591. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkersBiopsyCase-Control StudiesCohort StudiesFemaleGene FrequencyHepatitis, AutoimmuneHistocompatibility Antigens Class IIHumansIntramolecular OxidoreductasesLiverLiver Cirrhosis, BiliaryMacrophage Migration-Inhibitory FactorsMaleMicrosatellite RepeatsMiddle AgedPhenotypePolymorphism, Single NucleotideConceptsMacrophage migration inhibitory factorPrimary biliary cirrhosisAutoimmune hepatitisMigration inhibitory factorMIF receptorHealthy controlsInhibitory factorAutoimmune liver diseaseMIF promoter polymorphismsHepatic stellate cellsEnzyme-linked immunosorbentCATT7 alleleImmunopathogenic basisMIF expressionMIF locusBiliary cirrhosisLiver diseaseInflammatory phenotypeReceptor profileStellate cellsPromoter polymorphismPatientsSerum samplesCD74Single nucleotide polymorphisms
1987
Improved survival with primary sclerosing cholangitis A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients
Helzberg J, Petersen J, Boyer J. Improved survival with primary sclerosing cholangitis A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1987, 92: 1869-1875. PMID: 3569762, DOI: 10.1016/0016-5085(87)90618-4.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisIntrahepatic ductal systemSclerosing cholangitisClinicopathologic featuresDuctal systemKaplan-Meier life-table analysisLong-term prognosisGroup of patientsDifferent clinical characteristicsSerum bilirubin levelsOnset of diseaseUniversity Medical CenterLife-table analysisBiliary sclerosisAsymptomatic patientsPortal hypertensionClinical characteristicsLiver centersBilirubin levelsClinical featuresLiver diseaseMild diseasePoor prognosisMean ageFemale ratio
1985
Asymptomatic primary biliary cirrhosis A progress report on long-term follow-up and natural history
Beswick D, Klatskin G, Boyer J. Asymptomatic primary biliary cirrhosis A progress report on long-term follow-up and natural history. Gastroenterology 1985, 89: 267-271. PMID: 4007417, DOI: 10.1016/0016-5085(85)90325-7.Peer-Reviewed Original ResearchConceptsAsymptomatic primary biliary cirrhosisPrimary biliary cirrhosisBiliary cirrhosisAsymptomatic stateGeneral populationInitial liver biopsySubgroup of patientsLife table survival analysisDevelopment of symptomsMedian followPortal granulomasOverall survivalProgressive diseaseLiver biopsyLiver diseaseMedian periodAutoimmune disordersExtended followHistologic featuresBenign outcomeCirrhosisPatientsSurvival analysisNatural historySymptoms
1979
Nonalcoholic liver disease Overlooked causes of liver injury in patients with heavy alcohol consumption
Levin D, Baker A, Riddell R, Rochman H, Boyer J. Nonalcoholic liver disease Overlooked causes of liver injury in patients with heavy alcohol consumption. The American Journal Of Medicine 1979, 66: 429-434. PMID: 433949, DOI: 10.1016/0002-9343(79)91064-7.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseaseNonalcoholic liver diseaseLiver diseaseLiver biopsyHeavy alcohol consumptionAlcohol consumptionHepatitis B surface antigenSerum glutamic oxaloacetic transaminaseB surface antigenGlutamic oxaloacetic transaminaseAcute hepatitisChronic hepatitisTransaminase ratioConsecutive patientsLiver injuryAppropriate therapyClinical featuresLiver disordersOverlooked causeAlcoholic subjectsPatientsSurface antigenOxaloacetic transaminaseBiopsyDisease
1974
Variation in hepatic bile composition following cholecystectomy in patients with previous gallstones.
Boyer J, Bloomer J, Maddrey W, Tilson D. Variation in hepatic bile composition following cholecystectomy in patients with previous gallstones. The Yale Journal Of Biology And Medicine 1974, 47: 211-7. PMID: 4456833, PMCID: PMC2595121.Peer-Reviewed Original ResearchConceptsHepatic bileBile compositionEnterohepatic circulationBile acidsBile acid poolLithogenicity of bileHepatic bile compositionBile specimensDay study periodT-tubeCholesterol gallstonesPatientsExcretion rateCholecystectomyBileStudy periodGallstonesAcid poolAdmirandGallbladderLithogenicityCirculation
1973
Inhibition of Bilirubin Excretion in Man During Dehydrocholate Choleresis
Bloomer J, Boyer J, Klatskin G. Inhibition of Bilirubin Excretion in Man During Dehydrocholate Choleresis. Gastroenterology 1973, 65: 929-935. PMID: 4753351, DOI: 10.1016/s0016-5085(19)32986-5.Peer-Reviewed Original ResearchConceptsBilirubin excretionBilirubin concentrationExternal biliary drainagePlasma disappearance rateBiliary drainageBile flowCholeretic effectDilutional effectPatientsControl valuesExcretionSodium dehydrocholateControl periodDecholinDisappearance rateBileAdministrationMenCholeresisCumulative recovery